无锡福欣医药研究开发

Wuxi Fuxin Pharmaceutical Research and Development is a core R&D subsidiary of Fosun Pharma, established in 2013 and headquartered in Wuxi, China. The company specializes in the discovery and development of innovative small molecule drugs, with a strategic focus on oncology and rare diseases. Its pipeline includes several advanced clinical candidates, most notably the MEK inhibitor FCN-159 and the CDK4/6 inhibitor FCN-437, both of which are in late-stage clinical trials. Wuxi Fuxin leverages its parent company's extensive resources and global network to accelerate the translation of scientific discoveries into clinical therapies. The company is recognized for its expertise in medicinal chemistry and its commitment to addressing significant unmet medical needs. As an integral part of Fosun Pharma's innovation ecosystem, it plays a vital role in the group's long-term growth strategy.